NUR 544 Module 4 Application to Practice Theory Paper Example

Numb Fingers and a Dose Decision: Applying the Symptom Management Theory to Chemotherapy-Induced Peripheral Neuropathy

Student Name

Edson College of Nursing and Health Innovation, Arizona State University

NUR 544: Theoretical Foundations for Nursing

Instructor Name

Month Day, Year

Numb Fingers and a Dose Decision: Applying the Symptom Management Theory to Chemotherapy-Induced Peripheral Neuropathy

Introduction

Chemotherapy-induced peripheral neuropathy is one of the most persistent side effects of cancer treatment. Patients describe numb fingers that drop buttons, tingling feet that make stairs dangerous, and burning pain that keeps them awake. In an infusion center, nurses are often the first to hear these symptoms and must decide what to assess, what to teach and when to alert the oncologist. A middle-range theory can bring order to those decisions. Using one composite patient, this paper works through chemotherapy-induced neuropathy with the Symptom Management Theory.

The Symptom Management Theory

The Symptom Management Theory, developed at the University of California, San Francisco, describes symptom management through three dimensions: the symptom experience, symptom management strategies and symptom status outcomes (Dodd et al., 2001). The symptom experience includes a person's perception of the symptom, evaluation of its meaning and response to it. Management strategies include who delivers them, what they are, when, where, why, how much and how. Outcomes include functional status, quality of life, emotional status, costs and the symptom itself. These dimensions sit within three contextual domains: the person, such as demographic and developmental factors; health and illness, such as risk factors and disease; and environment, including social and cultural factors. The theory assumes that symptoms must be understood from the patient's perspective and that management begins with assessment of that experience (Smith et al., 2024).

Applying the Theory to Ms. R.

Ms. R. is a composite 61-year-old retired bookkeeper receiving weekly paclitaxel for breast cancer. At her ninth infusion, she mentions tingling in her fingertips and toes that has spread over two weeks.

Contextual Domains

Person: she lives alone, is right-handed and enjoys knitting and gardening. Health and illness: she has type 2 diabetes, which increases her risk of neuropathy, and paclitaxel is a well-known cause. Environment: her home has steep steps, and her daughter visits only on weekends.

Symptom Experience

Using the theory, I first assess her perception: when the tingling started, where it is, how intense it is, and whether it affects function. I ask what it means to her. Ms. R. worries she will no longer be able to knit, and she has started holding the stair rail with both hands. Her response so far has been to avoid telling the oncologist because she fears her treatment will be stopped.

Symptom Management Strategies

The theory asks who, what, when and how. The national guideline on chemotherapy-induced neuropathy states that no agents are recommended for preventing it, that clinicians should assess whether to delay, reduce, substitute or stop chemotherapy in patients who develop intolerable neuropathy or functional impairment, and that duloxetine is the only agent with appropriate evidence for established painful neuropathy, with limited benefit (Loprinzi et al., 2020). In this light, the most important strategy is not a drug but a decision. My role is to assess and document the neuropathy accurately, report it to the oncologist before her next dose, and help Ms. R. understand that a dose adjustment may protect her function without abandoning treatment. At home, strategies include fall prevention, checking feet daily because of her diabetes, and adapting tasks. I also explain that her honest reporting is what allows her care to be adjusted.

Symptom Status Outcomes

Outcomes to monitor include her functional status, such as buttoning, writing and stair safety; her quality of life, including whether she can knit; her emotional status, including fear about treatment; and the symptom itself, rated at each visit. If the oncologist reduces her dose, outcomes would show whether the neuropathy stabilizes.

How the Theory Informs Practice

The theory changed what I do in three ways. First, it moved my assessment from whether neuropathy is present to what it means and how the patient is responding, which revealed Ms. R.'s fear of reporting. Second, it framed management as a set of decisions about who, what and when, which highlighted that the key intervention is timely communication with the oncologist. Third, it defined outcomes in terms that matter to the patient, such as knitting and stairs, alongside symptom scores.

Using the Theory With the Team

The theory is also useful beyond one patient. Our infusion center sees dozens of patients on neurotoxic regimens each week, and assessment of neuropathy varies from nurse to nurse. Using the theory's dimensions, the unit could adopt a brief, structured neuropathy check at each visit: a rating of numbness, tingling and pain; two questions about function, such as buttoning and walking on stairs; and one question about meaning, such as what the patient is most worried about losing. Results would be documented in a consistent field and reported to the oncologist before each dose. That structure turns a middle-range theory into a shared practice and creates data the unit could use to see whether reporting improves. It also gives newer nurses a script for a conversation that patients often avoid.

Evaluating the Theory

The Symptom Management Theory is clear, general enough to apply to any symptom and practical for assessment and care planning. Its dimensions are measurable, which supports research and quality improvement. Its limitations include complexity in its contextual domains and less guidance on choosing among strategies when evidence is weak, as it is for preventing neuropathy. In practice, the theory works best paired with clinical guidelines that supply the evidence for specific strategies.

Conclusion

Applying the Symptom Management Theory to chemotherapy-induced peripheral neuropathy turned a vague complaint into a structured assessment, a clear decision and patient-centered outcomes. For Ms. R., it revealed that fear was keeping her from reporting, and it guided a nursing response that protected both her function and her treatment.

References

Dodd, M., Janson, S., Facione, N., Faucett, J., Froelicher, E. S., Humphreys, J., Lee, K., Miaskowski, C., Puntillo, K., Rankin, S., & Taylor, D. (2001). Advancing the science of symptom management. Journal of Advanced Nursing, 33(5), 668-676. https://doi.org/10.1046/j.1365-2648.2001.01697.x

Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., Schneider, B. P., Lavoie Smith, E. M., Smith, M. L., Smith, T. J., Wagner-Johnston, N., & Hershman, D. L. (2020). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. Journal of Clinical Oncology, 38(28), 3325-3348. https://doi.org/10.1200/JCO.20.01399

Smith, M. J., Liehr, P. R., & Carpenter, R. D. (Eds.). (2024). Middle range theory for nursing (5th ed.). Springer Publishing.